Helus Pharma closes $50M share offering at $4.85 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
June 25, 2026 9:28 AM EDTNEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the Company or Helus Pharma), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the Common Shares) at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the... More
